Jim Cramer on Immunome: “If You Want to Speculate on It, Fine”

Company Overview - Immunome, Inc. (NASDAQ:IMNM) is a clinical-stage biotech company focused on developing targeted cancer treatments, with a leading drug candidate in late-stage testing and another in early clinical trials [1] - The company has a pipeline that includes therapies aimed at treating solid tumors with more precise approaches [1] Recent Developments - On December 15, 2025, Immunome announced strong results from the Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors [1] - The drug demonstrated an 84% reduction in the risk of disease progression or death compared to placebo, a 56% response rate versus 9% for placebo, and an 83% reduction in tumor volume, with mostly mild to moderate side effects [2] Future Plans - Immunome plans to submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026 [2] - The primary investigator of the RINGSIDE trial, Dr. Mrinal M. Gounder, highlighted the significant benefits of varegacestat, suggesting it could become the standard of care for desmoid tumors [2]